Pharmacists, Unblinded Staff, Family Ties and Institutional Conflicts

Part of Conflict of Interest in Clinical Research: Conflicts by Role at the Site.

About 5 minutes. Free, in your language, no account needed.

Expert review pending. CRLN wrote this lesson against the primary sources listed under References. A subject-matter expert has not yet reviewed it. Where your institution's policy or your sponsor's instructions are stricter, follow them.

Why this matters

Some of the most consequential conflicts at a site sit outside the investigator's office. The research pharmacist and other unblinded staff hold information that could change everyone else's judgment. Family and close relationships cut across job titles. And the institution itself can have a stake that shapes decisions made far above the study team. This lesson covers all three.

Research pharmacists and unblinded staff

In a blinded trial, the people who know which participant received which treatment carry a special duty: to keep that knowledge from reaching anyone who assesses participants or handles blinded data. ICH E6(R3) says the investigator should ensure the randomization code is broken only in accordance with the protocol and should promptly document and explain any premature unblinding to the sponsor (Annex 1 §2.11). Roles and procedures for access to unblinded information should be defined and documented, and may be recorded in site staff delegation records (§4.1.2). Any planned or unplanned unblinding should be documented (§4.1.4).

Conflicts of interest make that duty harder to keep. Examples:

• Financial. An unblinded pharmacist who holds shares in the sponsor, or who consults for it, knows interim patterns that could inform trading or advice. The holding should be disclosed under your institution's policy even if the pharmacist is not an investigator under federal definitions.
• Professional. A pharmacist who hopes to co-author the site's results paper may be tempted to share "just a hint" with a blinded colleague.
• Personal. An unblinded pharmacist whose close friend or relative is a participant, or whose partner is the blinded rater, faces pressure to reassure or to warn.

Good practice: disclose such interests and relationships when you are delegated an unblinded role, and ask that any participant you have a personal tie to be handled by another unblinded team member where the trial design allows.

Family and close relationships across the team

Personal conflicts do not depend on money. Common site situations:

• A married couple on the same study, with one the investigator and the other the coordinator who prepares the data the investigator signs off.
• A manager supervising a relative whose performance includes study metrics.
• A team member whose spouse works for the sponsor or its CRO.

Federal financial rules already treat a spouse's and dependent children's financial interests as the investigator's own (21 CFR 54.2(d); 42 CFR 50.603). Beyond money, institutional policy usually decides how close relationships are handled, often by separating duties so that one person does not check the other's work. Tell the investigator and follow your site's policy.

Institutional conflicts of interest

An institutional conflict exists when the organization, or a senior official acting for it, has a financial interest that could affect research it conducts or oversees. Examples:

• the institution holds equity in, or a license to, the company that sponsors a study;
• the institution receives royalties on the product being tested;
• a dean, department chair or site owner with authority over the study team holds equity in or consults for the sponsor;
• a large gift from the sponsor to the institution is under negotiation while its trial is underway.

There is no single US federal regulation that governs institutional conflicts of interest the way 42 CFR Part 50 Subpart F governs investigator conflicts. Many universities and health systems have their own institutional conflict policies, often run by a committee separate from the one that reviews individual investigators. Independent sites and site networks may have none.

For staff, the signs to watch for are pressure from above on how a study is run, reported or promoted, and decisions about a study made by someone with a known stake. Raise them through your conflict office, your compliance office or the IRB. Module 5 covers escalation routes.

Independent sites and site networks

At a privately owned site, the owner may also be the principal investigator, the person who signs the clinical trial agreement and the person who sets staff pay. That concentration is not wrong in itself, but it means fewer independent checks. Practical safeguards include a written conflict of interest policy that covers owners, use of an independent IRB, documented separation of who signs off which data, and a named person outside the owner's line of authority to whom staff can raise concerns.

In practice

The research pharmacist at a hospital site learns that her brother has enrolled in the blinded trial she supports. She tells the investigator and the pharmacy manager the same day. The pharmacy reassigns her brother's dispensing to another unblinded pharmacist, the change is recorded in the delegation records, and she does not access his dispensing records.

Key takeaways

• Unblinded staff hold information that could change others' judgment; their interests and relationships need disclosure even outside federal definitions.
• E6(R3) requires that the randomization code be broken only per protocol and that access to unblinded information be defined and documented.
• Family and close relationships across the team are managed by separating duties.
• Institutional conflicts arise when the organization or its leaders have a stake; no single US federal rule governs them, so institutional policy and escalation routes matter.

References

• ICH E6(R3), Step 4, 6 January 2025: Annex 1 §2.3.1, §2.11, §4.1.2, §4.1.4.
• 21 CFR 54.2(d), eCFR.
• 42 CFR 50.603 and 50.604(a), eCFR.